SYD-101 contains a low dose of atropine sulfate, an antimuscarinic agent, in an ophthalmic solution. The NDA is supported by data from the phase 3 STAR trial (ClinicalTrials.gov Identifier ...

Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with ...

Because of the difficulty obtaining and risks associated with compounded drops, many eye care ... The STAR study is investigating SYD-101 (atropine sulfate ophthalmic solution 0.01% and 0.03% ...